Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP1 | P63208 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 6/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31013106 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CKS1BSKP1SKP2P2RY12 | |
| SCHEMBL24879104 | 0.87 | PTPN11 (0.33) | L3MBTL1ALDH1A1PTPN11OPRK1 | |
| SCHEMBL21115128 | 0.86 | PTPN11 (0.31) | L3MBTL1ALDH1A1MTORPTPN11 | |
| SCHEMBL22584688 | 0.85 | L3MBTL1 (0.40) | L3MBTL1CKS1BSKP1SKP2RET | |
| SCHEMBL23064011 | 0.85 | PTPN11 (0.36) | CKS1BSKP1SKP2PTPN11JAK3 | |
| SCHEMBL30511956 | 0.82 | OPRK1 (0.36) | L3MBTL1CKS1BSKP1SKP2P2RY12 | |
| SCHEMBL30296108 | 0.82 | OPRK1 (0.36) | L3MBTL1CKS1BSKP1SKP2P2RY12 | |
| SCHEMBL30511930 | 0.82 | OPRK1 (0.36) | L3MBTL1CKS1BSKP1SKP2P2RY12 | |
| SCHEMBL19785573 | 0.82 | OPRK1 (0.36) | L3MBTL1CKS1BSKP1SKP2P2RY12 | |
| SCHEMBL24879360 | 0.81 | PTPN11 (0.36) | CKS1BSKP1SKP2PTPN11JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109118-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2025-04-03 | — | — | US | disclosed |
| WO-2023122938-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023122938-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109118-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | PTPN1, PTPN5, PTPN13 | L3MBTL1 3307/4885CKS1B 1032/4885SKP1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.